HomeNewsWorldOxford/AstraZeneca vaccine set for clearance by year-end: Report

Oxford/AstraZeneca vaccine set for clearance by year-end: Report

The Oxford/AstraZeneca, AZD1222, vaccine has taken longer for regulators to assess because of differences in the efficacy rates found in different groups, ranging from 62 to 90 percent.

December 20, 2020 / 18:17 IST
Story continues below Advertisement
Source: Reuters
Source: Reuters

The Oxford University vaccine against COVID-19 being produced by AstraZeneca is likely to get regulatory approval from the UK's independent regulator by the end of this year for a rollout to begin in early 2021, according to a UK media report.

The Medicines and Healthcare Regulatory Agency (MHRA), which had been formally tasked by the UK government last month with the process of clearance after the jab emerged safe and effective against the novel coronavirus in human trials, is expected to authorise the vaccine by December 28 or 29 after the final data is provided on Monday, The Daily Telegraph' quoted senior government sources as indicating.

Story continues below Advertisement

Authorisation by the MHRA will also give confidence to countries across the world. India has already manufactured more than 50 million of the AstraZeneca vaccines, the newspaper notes. In India, the vaccine is being produced as part of a tie-up with the Serum Institute of India.

Health officials in the UK hope that the authorisation of the Oxford jab will prove a game-changer, allowing vaccines to be transported and administered far more easily compared to the Pfizer/BioNTech vaccine which must be stored at very cold temperatures. The Oxford vaccine can be stored in normal refrigerators but like the Pfizer vaccine, it also requires two doses with a three-week gap between the two doses for the Pfizer jabs and a four-week gap for the Oxford/AstraZeneca vaccine.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show